PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Posttranslational modifications to the intracellular domain of the EGFR are known to regulate EGFR functions; however, modifications to the extracellular domain and their effects remain relatively unexplored. Here, we determined that methylation at R198 and R200 of the EGFR extracellular domain by protein arginine methyltransferase 1 (PRMT1) enhances binding to EGF and subsequent receptor dimerization and signaling activation. In a mouse orthotopic colorectal cancer xenograft model, expression of a methylation-defective EGFR reduced tumor growth. Moreover, increased EGFR methylation sustained signaling activation and cell proliferation in the presence of the therapeutic EGFR monoclonal antibody cetuximab. In colorectal cancer patients, EGFR methylation level also correlated with a higher recurrence rate after cetuximab treatment and reduced overall survival. Together, these data indicate that R198/R200 methylation of the EGFR plays an important role in regulating EGFR functionality and resistance to cetuximab treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, methylation at R198 and R200 of the EGFR ECD plays an essential role in regulating EGFR functionality and resistance to cetuximab treatment in CRC patients [145].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [145]
In the citing paper
“In addition, R198/R200 methylation and mutation in the kinase domain of EGFR (V843I) correlated with disease progression in the presence of cetuximab [69].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118 · cited 1×
“Upon binding, cetuximab occludes the EGF-binding site and prevents EGFR from adopting the active conformation required for ligand binding and dimerization (47).”
BackgroundProtein arginine methyltransferases and cancer
Yang, Y., & Bedford, M. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3409 · Cited by 1,083 · cited 1×
“During arginine methylation, PRMTs transfer methyl groups from S-adenosylmethionine (SAM) to the guanidine nitrogen of specific arginine residues on their target proteins, which in turn alter the protein structure, protein-protein interaction, protein localization, and enzyme activity that are critical for various cel…”
BackgroundDe Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H.-S., Leahy, D. J., & Lemmon, M. A. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00047-9 · Cited by 801
Research works printed but not linked: 1
- E-mail: mhung@mdanderson.org. jci.org Volume 125 Number 12 December 2015 activity. Cell Cycle. 2005;4(12):1834-1841.
Cited by
Arginine Methylation: The Coming of Age
Blanc, R. S., & Richard, S. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.11.003 · Cited by 1,054
“Importantly, EGFR methylation levels correlated with higher reappearance rates after therapeutic EGFR monoclonal antibody Cetuximab treatment and reduced survival (Liao et al., 2015).”
BackgroundGenetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“Enhanced EGFR activation can occur via post-translational modifications involving methylation of R198 and R200 by protein arginine methyltransferase 1 (PRMT1), which enhances its binding to EGF and consequent signaling activation, even in the presence of the EGFR inhibitor (Liao et al. 2015).”
BackgroundThe role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
“EGFR mAb resistance in colorectal cancer [203].”
Self-citationThe molecular basis of endothelial cell plasticity
Dejana, E., Hirschi, K. K., & Simons, M. (2017) · Nature Communications · doi:10.1038/ncomms14361 · Cited by 441
Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis
Chen, P.-Y., Qin, L., Li, G., Wang, Z., Dahlman, J. E., Malagon-Lopez, J., Gujja, S., Cilfone, N. A., Kauffman, K. J., Sun, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0102-3 · Cited by 346
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
Chen, J., Zeng, F., Forrester, S. J., Eguchi, S., Zhang, M.-Z., & Harris, R. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00030.2015 · Cited by 327
EGF receptor ligands: recent advances
Singh, B., Carpenter, G., & Coffey, R. J. (2016) · F1000Research · doi:10.12688/f1000research.9025.1 · Cited by 323
A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
Nakai, K., Hung, M., & Yamaguchi, H. (2016) · Europe PMC (PubMed Central) · Cited by 421
Self-citationTransforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility
Budi, E. H., Duan, D., & Derynck, R. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.04.005 · Cited by 289
Protein arginine methyltransferases: promising targets for cancer therapy
Hwang, J. W., Cho, Y., Bae, G.-U., Kim, S.-N., & Kim, Y. K. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00613-y · Cited by 268
Zhou, J., Ji, Q., & Li, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02130-2 · Cited by 246
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise
Westphal, M., Maire, C. L., & Lamszus, K. (2017) · CNS Drugs · doi:10.1007/s40263-017-0456-6 · Cited by 221
“This led to increased activation of the receptor, counteracting the effect of cetuximab in a mouse model of colon cancer [118].”
BackgroundThe Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Cai, W.-Q., Zeng, L.-S., Wang, L.-F., Wang, Y.-Y., Cheng, J.-T., Zhang, Y., Han, Z.-W., Zhou, Y., Huang, S.-L., Wang, X.-W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01249 · Cited by 196
Self-citationMethylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis
Li, Z., Wang, D., Lu, J., Huang, B., Wang, Y., Dong, M., Fan, D., Li, H., Gao, Y., Hou, P., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-00615-9 · Cited by 196
Self-citationUpdated Insights on EGFR Signaling Pathways in Glioma
Oprita, A., Baloi, S.-C., Staicu, G.-A., Alexandru, O., Tache, D. E., Danoiu, S., Micu, E. S., & Sevastre, A.-S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020587 · Cited by 160
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
CARM1 Methylates GAPDH to Regulate Glucose Metabolism and Is Suppressed in Liver Cancer
Zhong, X.-Y., Yuan, X.-M., Xu, Y.-Y., Yin, M., Yan, W.-W., Zou, S.-W., Wei, L.-M., Lu, H.-J., Wang, Y.-P., & Lei, Q.-Y. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.066 · Cited by 158
Self-citationYao, B., Gui, T., Zeng, X., Deng, Y., Wang, Z., Wang, Y., Yang, D., Li, Q., Xu, P., Hu, R., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00871-5 · Cited by 141
“Results are shown as mean ± s.d.; *P < 0.05 compared with the control mice. i Survival curves of ApcMin/+-PBS (n = 12) and ApcMin/+-AMI-1 (n = 12) mice.”
BackgroundMethodInfluentialSelf-citationProtein arginine methylation/demethylation and cancer
Poulard, C., Corbo, L., & Romancer, M. L. (2016) · Oncotarget · doi:10.18632/oncotarget.11376 · Cited by 155
“Regulates DNA damage response Initiates BMP-Induced Smad Signaling Impeeds Akt phosphorylation Prerequisite for Akt activation Allows the binding of TDRD3 Stabilization from proteosomal degradation Negatively regulates cell apoptosis Prevent the corepressor SIN3A binding IFNalpha/beta-induced transcription Required fo…”
BackgroundParseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
“(70) In particular, they reported a post-translational arginine methylation on the extracellular domain of EGFR by protein arginine methyltransferase (PRMT) 1 at R198 and R200 that resulted in increased ligand binding to promote EGFR receptor dimerization and activation, and alters EGFR signaling.(70)”
BackgroundSelf-citationEndothelial-to-Mesenchymal Transition, Vascular Inflammation, and Atherosclerosis
Chen, P., Schwartz, M. A., & Simons, M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00053 · Cited by 125
Structure, Activity, and Function of PRMT1
Thiébaut, C., Eve, L., Poulard, C., & Romancer, M. L. (2021) · Life · doi:10.3390/life11111147 · Cited by 120
Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 113
“PRMT1 plays an important role in hematologic malignancies [103] and solid tumors [132, 133], although just one PRMT1 inhibitor (GSK3368715) is currently in development.”
BackgroundILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer
Li, K., Wu, J.-L., Qin, B., Fan, Z., Tang, Q., Lu, W., Zhang, H., Xing, F., Meng, M., Zou, S., et al. (2020) · Cell Research · doi:10.1038/s41422-019-0257-1 · Cited by 106
Self-citationPRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia
He, X., Zhu, Y., Lin, Y., Li, M., Du, J., Dong, H., Sun, J., Zhu, L., Wang, H., Ding, Z., et al. (2019) · Blood · doi:10.1182/blood.2019001282 · Cited by 106
Self-citationSmooth muscle FGF/TGFβ cross talk regulates atherosclerosis progression
Chen, P., Qin, L., Li, G., Tellides, G., & Simons, M. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506181 · Cited by 87
Histone methyltransferase and drug resistance in cancers
Yang, C., Zhang, J., Ma, Y., Wu, C., Cui, W., & Wang, L. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01682-z · Cited by 90
Katsuno, Y., Qin, J., Osés-Prieto, J. A., Wang, H., Jackson‐Weaver, O., Zhang, T., Lamouille, S., Wu, J., Burlingame, A. L., Xu, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002027 · Cited by 84
Self-citationProtein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
Vinet, M., Suresh, S., Maire, V., Monchecourt, C., Némati, F., Lesage, L., Pierre, F., Ye, M., Lescure, A., Brisson, A., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2114 · Cited by 83
Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance
Zhu, Y., Xia, T., Chen, D.-Q., Xiong, X., Shi, L., Zuo, Y., Xiao, H., & Liu, L. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101016 · Cited by 88
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Braig, F., Kriegs, M., Voigtlaender, M., Habel, B., Grob, T. J., Biskup, K., Blanchard, V., Sack, M., Thalhammer, A., Batalla, I. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0754 · Cited by 87
Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery
Rosenkranz, A. A., & Slastnikova, T. A. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920090011 · Cited by 81
PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer
Yin, X.-K., Wang, Y., Wang, F., Feng, W.-X., Bai, S.-M., Zhao, W.-W., Feng, L.-L., Wei, M., Qin, C.-L., Wang, F., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01617-0 · Cited by 73
Self-citationPRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis
Li, Z., Wang, D., Chen, X., Wang, W., Wang, P., Hou, P., Li, M., Chu, S., Qiao, S., Zheng, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04381-5 · Cited by 74
Giannou, A. D., Kempski, J., Shiri, A. M., Lücke, J., Zhang, T., Zhao, L., Zazara, D. E., Cortesi, F., Riecken, K., Vesely, M. C. A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.014 · Cited by 74
Zhang, Y. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.123.000906 · Cited by 74
“Liao et al. showed that EGFR methylation in its ECD renders it less sensitive to cetuximab (Liao et al., 2015).”
BackgroundNakai, K., Xia, W., Liao, H.-W., Saito, M., Hung, M., & Yamaguchi, H. (2017) · Breast Cancer · doi:10.1007/s12282-017-0790-z · Cited by 68
Self-citationPRMT1 promotes pancreatic cancer growth and predicts poor prognosis
Song, C., Chen, T., He, L., Ma, N., Li, J., Rong, Y., Fang, Y., Liu, M., Xie, D., & Lou, W. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00435-1 · Cited by 66
Self-citationWang, Y., Hsu, J.-M., Kang, Y., Wei, Y., Lee, P., Chang, S.-J., Hsu, Y.-H., Hsu, J. L., Wang, H.-L., Chang, W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0715 · Cited by 69
“The arginine methylation mediated by PRMT1 positively or negatively affects protein functions depending on the biological contexts (26,27), and our recent work further revealed an important function of PRMT1 on EGFR regulation in colon cancer (28).”
Self-citationZhao, J., Adams, A., Roberts, B., O’Neil, M. F., Vittal, A., Schmitt, T. M., Kumer, S. C., Cox, J., Li, Z., Weinman, S. A., et al. (2018) · Hepatology · doi:10.1002/hep.29587 · Cited by 68
“PRMT1 also regulates other transcription factors that are involved in regulation of cell-cycle progression and proliferation, such as FOXOs,((22)) p53,((6)) cMyc,((2,39)) as well as upstream signaling molecules involved in proliferation, epidermal growth factor receptor.((40)) We analyzed PRMT1 KO mouse gene FIG.”
Wang, C., Jiang, H., Jin, J., Xie, Y., Chen, Z., Zhang, H., Lian, F., Liu, J. Y.-C., Zhang, C., Ding, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01134 · Cited by 65
Non-Histone Arginine Methylation by Protein Arginine Methyltransferases
Al-Hamashi, A. A., Diaz, K., & Huang, R. (2020) · Current Protein and Peptide Science · doi:10.2174/1389203721666200507091952 · Cited by 62
Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair
Liu, L., Lin, B., Yin, S., Ball, L. E., Delaney, J. R., Long, D. T., & Gan, W. (2022) · Science Advances · doi:10.1126/sciadv.add8928 · Cited by 66
Saloura, V., Vougiouklakis, T., Zewde, M. G., Deng, X., Kiyotani, K., Park, J.-H., Matsuo, Y., Lingen, M. W., Suzuki, T., Dohmae, N., et al. (2017) · Scientific Reports · doi:10.1038/srep40664 · Cited by 57
“More recently, Liao et al. 14 reported that PRMT1-mediated methylation of R198/200 in the extracellular domain of EGFR enhances its binding to EGF and its homodimerization, and activates both the RAS-RAF-MEK-ERK and the PI3K-AKT growth-signaling pathways in colon cancer cells.”
Zhu, Y., He, X., Lin, Y., Dong, H., Zhang, L., Chen, X., Wang, Z., Shen, Y., Li, M., Wang, H., et al. (2019) · Blood · doi:10.1182/blood.2019002457 · Cited by 56
Self-citationWang, L., Jia, Z., Xie, D., Zhao, T., Tan, Z., Zhang, S., Kong, F., Wei, D., & Xie, K. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1738 · Cited by 58
The arginine methyltransferase PRMT1 regulates IGF-1 signaling in breast cancer
Choucair, A., Pham, T. H., Omarjee, S., Jacquemetton, J., Kassem, L. M. H., Trédan, O., Rambaud, J., Marangoni, E., Corbo, L., Treilleux, I., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0694-9 · Cited by 56
Ryu, T. Y., Kim, K., Son, M., Min, J., Kim, J., Han, T.-S., Kim, D., & Cho, H. (2018) · Oncology Reports · doi:10.3892/or.2018.6938 · Cited by 51
“Subsequently, the ERK and AKT pathways were activated for survival during cetuximab treatment (16).”
BackgroundPRMT1-Dependent Macrophage IL-6 Production Is Required for Alcohol-Induced HCC Progression
Zhao, J., O’Neil, M. F., Vittal, A., Weinman, S. A., & Tikhanovich, I. (2018) · Gene Expression · doi:10.3727/105221618x15372014086197 · Cited by 50
Yan, Z., Wu, H. M., Liu, H., Zhao, G., Zhang, H., Zhuang, W., Liu, F., Zheng, Y., Liu, B., Zhang, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109731 · Cited by 51
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment
Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 58
Suresh, S., Huard, S., Brisson, A., Némati, F., Dakroub, R., Poulard, C., Ye, M., Martel, E., Réyès, C., Silvestre, D. C., et al. (2022) · Cancers · doi:10.3390/cancers14020306 · Cited by 43
“We also detected PRMT1 at the plasma membrane, preferentially in 332 the ER-negative BC subtypes, possibly since it interacts with some transmembrane 333 receptors such as EGFR (19,20) or IGF-1R (42).”
BackgroundBao, J., Lorenzo, A. D., Lin, K., Lu, Y., Zhong, Y., Sebastian, M. M., Muller, W. J., Yang, Y., & Bedford, M. T. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1995 · Cited by 43
“15 overexpression was shown to amplify the activation of AKT pathway in colorectal cancer cell lines (36), but this is the first in vivo data supporting this link.”
PRMT1 reverts the immune escape of necroptotic colon cancer through RIP3 methylation
Zhang, L., He, Y., Jiang, Y., Wu, Q., Liu, Y., Xie, Q., Zou, Y., Wu, J., Zhang, C., Zhou, Z., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05752-w · Cited by 43
“PRMT1 has been known as an oncogene via stimulating cancer cell proliferation or blocking apoptosis [36, 39], while the opposite findings have also been reported in some experiments in which PRMT1 might inhibit proliferation and promote apoptosis in cancer [37, 38].”
BackgroundResultZheng, N., Zhou, M., Sun, F. Z., Huai, M., Zhang, Y., Qu, C.-Y., Shen, F., & Xu, L. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i26.3737 · Cited by 41
PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells
He, L., Hu, Z., Sun, Y., Zhang, M., Zhu, H., Jiang, L., Zhang, Q., Mu, D., Zhang, J., Gu, L., et al. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102953 · Cited by 41
Saloura, V., Vougiouklakis, T., Sievers, C. M., Burkitt, K., Nakamura, Y., Hager, G. L., & Waes, C. V. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.04.014 · Cited by 40
“Recently, PRMT1 was found to mono-methylate arginine R198 and R200 of the extracellular domain of the epidermal growth factor receptor (EGFR), enhancing EGF binding and subsequent EGFR dimerization and EGFR downstream activation [35].”
BackgroundHe, Q., Qu, M., Bao, H., Xu, Y., Shen, T., Tan, D., Barkat, M. Q., Xu, C., Zeng, L., & Wu, X. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.003 · Cited by 43
Lipotoxicity-Induced PRMT1 Exacerbates Mesangial Cell Apoptosis via Endoplasmic Reticulum Stress
Park, M.-J., Han, H. J., & Kim, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071421 · Cited by 41
“reported that PRMT1 can be localized in the ER lumen [24].”
BackgroundEpidermal Growth Factor Receptor Expression in the Corneal Epithelium
Peterson, J. L., & Ceresa, B. P. (2021) · Cells · doi:10.3390/cells10092409 · Cited by 40
“While the basis for these disparities is not clear, these differences may reflect cellular changes in receptor methylation [67], the presence of corneal epithelial specific effectors, or perturbations in receptor trafficking [68].”
BackgroundFedoriw, A., Shi, L., O’Brien, S. W., Smitheman, K. N., Wang, Y., Hou, J., Sherk, C. S., Rajapurkar, S., Laraio, J., Williams, L. J., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0614 · Cited by 43
Self-citationChuang, C., Chang, C.-P., Lee, Y.-J., Lin, W.-L., Chang, W., Wu, J.-S., Cheng, Y., Lee, H., & Li, C. (2017) · Oncology Reports · doi:10.3892/or.2017.5737 · Cited by 36
“Colon cancer as well as HNC patients with higher levels of methyl-EGFR in tumors have been shown to have a higher recurrence rate after cetuximab treatment (11).”
BackgroundSelf-citationPicardo, F., Romanelli, A., Muinelo‐Romay, L., Mazza, T., Fusilli, C., Parrella, P., Barbazán, J., López‐López, R., Barbano, R., Robertis, M. D., et al. (2019) · Cancers · doi:10.3390/cancers11101598 · Cited by 38
“Several lines of evidence suggest that post-translational modifications of EGFR, such as phosphorylation of the cytoplasmic domain [44] or glycosylation can strongly influence the EGFR conformation, its activation [45,46], and the efficiency of antibody-based therapies [47,48], paving the way to explore a wide spectru…”
BackgroundHsu, W.-J., Chiang, M., Chao, Y., Chang, Y., Hsu, M.-C., Chung, C.-H., Tsai, I., Chu, C., Wu, H., Yang, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3829 · Cited by 36
Hepatocyte PRMT1 protects from alcohol induced liver injury by modulating oxidative stress responses
Zhao, J., Adams, A., Weinman, S. A., & Tikhanovich, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-45585-2 · Cited by 36
Hsu, D. S., Hwang, W., Yuh, C., Chu, C.-H., Ho, Y.-H., Chen, P.-B., Lin, H.-S., Lin, H., Wu, S.-P., Lin, C.-Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1955 · Cited by 38
“We recently demonstrated that methylation of the extracellular domain of EGFR promotes cetuximab resistance (13).”
BackgroundInfluentialSelf-citationCheng, C., Chang, J., Huang, S. C., Lin, H.-C., Ho, A., Lim, K., Chang, C.-C., Huang, L., Chang, Y., Chang, Y.-F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182149 · Cited by 36
PRMT1 in human neoplasm: cancer biology and potential therapeutic target
Shen, S., Zhou, H., Xiao, Z., Zhan, S., Tuo, Y., Chen, D., Pang, X., Wang, Y., & Wang, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01506-z · Cited by 38
“This facilitates receptor dimerization and signal activation, ultimately promoting cancer cell growth and conferring resistance to cetuximab treatment [87].”
BackgroundSelf-citationYang, L., Bhattacharya, A., Li, Y., Sexton, S., Ling, X., Li, F., & Zhang, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02389-z · Cited by 32
“Another study shows that EGFR methylation in its extracellular domain renders EGFR insensitive to cetuximab [45].”
BackgroundPRMT1 promotes pancreatic cancer development and resistance to chemotherapy
Ku, B., Eisenbarth, D., Baek, S., Jeong, T.-K., Kang, J., Hwang, D., Noh, M., Choi, C., Choi, S., Seol, T., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101461 · Cited by 38
“39,40 Furthermore, PRMT1-depen-dent methylation of the histone methyltransferase EZH2 and the transcription factor CEBPA suggests an important role of PRMT1 in the development of breast cancer.”
BackgroundAlbadari, N. G., Xie, Y., & Li, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1340401 · Cited by 38
“…increased methylation at R198 and R200 of the ECD of EGFR by protein arginine methyltransferase 1 (PRMT1) sustained signaling activation in the presence of cetuximab and conferred resistance to cetuximab treatment in both mouse orthotopic CRC xenograft model and CRC patients (Liao et al., 2015).”
BackgroundHow Protein Methylation Regulates Steroid Receptor Function
Malbeteau, L., Pham, T. H., Eve, L., Stallcup, M. R., Poulard, C., & Romancer, M. L. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab014 · Cited by 33
Meng, X., Zhao, Y., Liu, J., Wang, L., Dong, Z., Zhang, T., Gu, X., & Zheng, Z. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7808 · Cited by 34
“Furthermore, it is worth mentioning that these genes also have important roles in drug resistance (47,48).”
BackgroundCancer synthetic vulnerabilities to protein arginine methyltransferase inhibitors
Guccione, E., Schwarz, M. C., Tullio, F. D., & Mzoughi, S. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.04.004 · Cited by 28
PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
Hsu, W.-J., Chen, C., Chang, Y., Cheng, C., Tsai, Y.-H., & Lin, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101009 · Cited by 26
“Moreover, PRMT1 methylated an epidermal growth factor (EGF) receptor to regulate EGF signaling and confer resistance to cetuximab [38].”
BackgroundSelf-citationArginine methylation by PRMT2 promotes IFN-β production through TLR4/IRF3 signaling pathway
Wang, J., Hua, H., Wang, F., Yang, S., Zhou, Q., Wu, X., Feng, D., & Peng, H. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.08.014 · Cited by 24
Protein Arginine Methyltransferase PRMT1 Is Essential for Palatogenesis
Gou, Y., Li, J., Jackson‐Weaver, O., Wu, J., Zhang, T., Gupta, R., Cho, I., Ho, T., Chen, Y., Li, M., et al. (2018) · Journal of Dental Research · doi:10.1177/0022034518785164 · Cited by 25
“Similarly, PRMT1 induces overactivation of EGF signaling and sustained cell proliferation through methylation of EGFR (Liao et al. 2015).”
Gao, Y., Feng, C., Ma, J., & Yan, Q. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116048 · Cited by 28
Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma
Xu, J., Chang, W., Fong, L. W. R., Weiss, R. H., Yu, S., & Chen, C. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0035-z · Cited by 25
Self-citationRole of PRMT1 and PRMT5 in Breast Cancer
Martinez, S., Sentis, S., Poulard, C., Trédan, O., & Romancer, M. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168854 · Cited by 27
“[64].”
Prmt1 regulates craniofacial bone formation upstream of Msx1
Gou, Y., Li, J., Wu, J., Gupta, R., Cho, I., Ho, T., Chai, Y., Merrill, A. E., Wang, J., & Xu, J. (2018) · Mechanisms of Development · doi:10.1016/j.mod.2018.05.001 · Cited by 21
PARP inhibitors as precision medicine for cancer treatment
Du, Y., Yamaguchi, H., Hsu, J. L., & Hung, M. (2017) · National Science Review · doi:10.1093/nsr/nwx027 · Cited by 20
Self-citationOld dog, new tricks: extracellular domain arginine methylation regulates EGFR function
Epstein, D. M., & Buck, E. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci85001 · Cited by 21
Nair, S., Trummell, H. Q., Rajbhandari, R., Thudi, N. K., Nozell, S. E., Warram, J. M., Willey, C. D., Yang, E. S.-H., Placzek, W. J., Bonner, J. A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229077 · Cited by 25
Zhao, J., O’Neil, M. F., Schonfeld, M. P., Komatz, A., Weinman, S. A., & Tikhanovich, I. (2020) · Hepatology Communications · doi:10.1002/hep4.1488 · Cited by 22
“PRMT1 is known to promote proliferation of many cancer cell lines in vitro and in vivo,(16,17,20-22) including hepatoma cell lines.”
BackgroundRainczuk, A. K., Klatt, S., Yamaryo‐Botté, Y., Brammananth, R., McConville, M. J., Coppel, R. L., & Crellin, P. K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.011688 · Cited by 19
Jiang, L., Liao, J., Liu, J., Wei, Q., & Wang, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16725 · Cited by 20
Self-citationMethylation of HBP1 by PRMT1 promotes tumor progression by regulating actin cytoskeleton remodeling
Wang, J., Yang, R., Cheng, Y., Zhou, Y., Zhang, T., Wang, S., Li, H., Jiang, W., & Zhang, X. (2022) · Oncogenesis · doi:10.1038/s41389-022-00421-7 · Cited by 20
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Towards the Targeted Protein Degradation of PRMT1
Martin, P. L., Pérez-Areales, F. J., Rao, S. V., Walsh, S. J., Carroll, J. S., & Spring, D. R. (2024) · ChemMedChem · doi:10.1002/cmdc.202400269 · Cited by 20
Intracaecal Orthotopic Colorectal Cancer Xenograft Mouse Model
Liao, H.-W., & Hung, M. (2017) · BIO-PROTOCOL · doi:10.21769/bioprotoc.2311 · Cited by 17
Self-citationTRIM21-mediated PRMT1 degradation attenuates colorectal cancer malignant progression
Cao, M., Shao, Z., Qian, X., Chen, M., Deng, C., Chen, X., Tang, T., Zhang, K., Chu, S., Zheng, J., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07383-9 · Cited by 15
Inhibition of Arginine Methylation Impairs Platelet Function
Marsden, A. J., Riley, D. R. J., Barry, A., Khalil, J. S., Guinn, B., Kemp, N. T., Rivero, F., & Beltrán-Álvarez, P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00135 · Cited by 14
Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity
Itonaga, H., Mookhtiar, A. K., Greenblatt, S. M., Liu, F., Martínez, C., Bilbao, D., Rains, M., Hamard, P.-J., Sun, J., Umeano, A. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47689-4 · Cited by 15
Self-citationBiomedical effects of protein arginine methyltransferase inhibitors
Cao, M., Nguyen, T., Song, J., & Zheng, Y. G. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108201 · Cited by 15
“EPZ015666 possesses potent inhibitory properties against CRC harboring mutations in the KRAS gene, a mutation prevalent in approximately 45% of all CRC cases (129).”
InfluentialProtein post-translational modifications: A key factor in colorectal cancer resistance mechanisms
Bi, B., Qiu, M., Liu, P. F., Wang, Q., Wen, Y., Li, Y., Li, B., Li, Y., He, Y., & Zhao, J. (2023) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2023.194977 · Cited by 19
Systematic analysis of the intersection of disease mutations with protein modifications
Simpson, C. M., Zhang, B., Hornbeck, P. V., & Gnad, F. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0543-2 · Cited by 16
Dakroub, R., Huard, S., Younes, Y. H., Suresh, S., Badran, B. M., Fayyad‐Kazan, H., & Dubois, T. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s430513 · Cited by 16
Shimomura, M., Fukuda, T., Awazu, Y., Nanno, S., Inoue, Y., Matsubara, H., Yamauchi, M., Yasui, T., & Sumi, T. (2020) · Oncology Letters · doi:10.3892/ol.2020.12411 · Cited by 13
Metadata
- Authors
- Liao, H.-W., Hsu, J.-M., Xia, W., Wang, H.-L., Wang, Y.-N., Chang, W.-C., Arold, S. T., Chou, C.-K., Tsou, P.-H., Yamaguchi, H., Fang, Y.-F., Lee, H.-J., Lee, H.-H., Tai, S.-K., Yang, M.-H., Morelli, M. P., Sen, M., Ladbury, J. E., Chen, C.-H., Grandis, J. R., Kopetz, S., & Hung, M.-C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- University of Pittsburgh (US)
- University of Leeds (GB)
- Genomics Research Center, Academia Sinica (TW)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2015-11-16
- Volume
- 125
- Issue
- 12
- Pages
- 4529-4543
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC4665782
- OpenAlex
- W2176390318
- Cited by
- 155
- References
- 60
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 15 · 2023: 15 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 16 · 2018: 11 · 2017: 15 · 2016: 8 · 2015: 1
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- King Abdullah University of Science and Technology Repository (King Abdullah University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (CCSG CA 16672, CA 016672, CA109311, R01CA109311, P01CA099031, P30CA016672, P50CA097190, CA 099031)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- EGFR, PRMT1, arginine methylation, cetuximab resistance, EGFR signaling, receptor dimerization, colorectal cancer, tumor recurrence, overall survival, monoclonal antibody therapy
- MeSH terms
- Cetuximab, Animals, Colonic Neoplasms, Female, Humans, Methylation, Mice, Nude, Neoplasm Transplantation, Protein-Arginine N-Methyltransferases, Repressor Proteins, Signal Transduction, Cell Line, Tumor, Mice, Heterografts, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.